41P Switch from cetuximab (CET) to panitumumab (PANI) during encorafenib (ENCO)-based therapy in BRAF V600E mutated metastatic colorectal cancer (mCRC): An international multicenter analysis from the AGEO group
Title:
41P Switch from cetuximab (CET) to panitumumab (PANI) during encorafenib (ENCO)-based therapy in BRAF V600E mutated metastatic colorectal cancer (mCRC): An international multicenter analysis from the AGEO group
Author:
Gandini, A. Landi, M.B. De Grandis, M.C. Probst, V. Girot, P. Pastorino, A. Decraecker, M. Jones, J.C. Grados, L. Sayah, L. Trouilloud, I. Tougeron, D. Taieb, J.